Global Osteoarthritis Therapeutics Market By Anatomy (Knee, Hip, Hand, Small-joint), By Drug Type (Viscosupplementation agents, NSAIDs, Analgesics, Corticosteroids), By Route of Administration (Oral, Topical, Parenteral), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Region, Industry Analysis, Share, Growth, Trends, and Forecast, 2021-2028

Covid-19 Impact on Global Osteoarthritis Therapeutics Market

Type: PDF

Status: Published

Categories: Pharma & Healthcare

Report Code : PHC214052

No. of Pages : 287

The global osteoarthritis therapeutics market is expected to grow from USD 7.4 billion in 2020 to USD 14.6 billion by 2028 at a CAGR of 8.9 % over the forecast period 2021-2028.

Market Overview:

Osteoarthritis is a common joint disease found mostly in older people. It is characterized by the progressive destruction of articular cartilage, synovial inflammation, subchondral bone changes, and peri-articular muscle. The growing geriatric population, rising prevalence of osteoarthritis, and increasing per capita healthcare expenditure will drive the market growth during the forecast period. Also, the significant adoption of pain medications, the growing population vulnerable to osteoarthritis, and the rising number of sports injuries are driving factors of the global osteoarthritis therapeutic market. The preference for personalized medicines for osteoarthritis and collaborations for drug development will expand the market.

Market Dynamics:

Drivers:

Increasing govt. Investment in cell-based research

Increasing adoption of pain medications

Restraints:

Adverse effects of osteoarthritis therapeutic drugs

Key Market Players:

Sanofi, Horizon Therapeutics PLC, Johnson & Johnson, GlaxoSmithKline PLC, Bayer AG, Abbott, Pfizer, Eli Lilly, Anika Therapeutics, Novartis AG, Ferring Pharmaceuticals, Bioventus, Zimmer Biomet Holdings, Fidia Farmaceutici s.p.a., Flexion Therapeutics, Pharmed Limited, Virchow Biotech are some of the prominent players in the global osteoarthritis therapeutics market.

The market is segmented based on the below-mentioned segments:

On the Basis of Anatomy: Revenue & Volume

o Knee

o Hip

o Hand

o Small-joint

On the Basis of Drug Type: Revenue & Volume

o Viscosupplementation agents

o NSAIDs

o Analgesics

o Corticosteroids

On the Basis of Route of Administration: Revenue & Volume

o Oral

o Topical

o Parenteral

On the Basis of Distribution Channel: Revenue & Volume

o Hospital Pharmacies

o Online Pharmacies

o Retail Pharmacies

On The Basis of Region: Revenue & Volume

North America

- U.S.A
- Canada
- Mexico

Europe

- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe

Asia Pacific

- China
- Japan
- India
- SEA
- Australia
- Rest Of APAC

South America

- Brazil
- Argentina
- Rest of South America

Middle East & Africa

- South Africa
- Saudi Arabia
- UAE
- Rest of MEA

Report Description

Year Consideration
- Base year – 2020
- Historic Year-2017-2019
- Forecast year- 2021 to 2028

The global osteoarthritis therapeutics market will be based on revenue and volume. The study covers the market share for segments, countries, regions, and players.

The regions evaluated for the global osteoarthritis therapeutics market are Europe, North America, Asia Pacific, South America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country-level.

The report provides an in-depth pricing analysis, value chain analysis, industry road map, and micro and macro factors.

The research report further provides the attractiveness of osteoarthritis therapeutics and regions based on their growth rate (CAGR), market size, and attractiveness by analyzing present and future prospects to analyze market growth and development in the future.

Also, the study focuses on market-related driving forces, restraints, potential opportunities for the market, significant developments, and advancement that serve as a key potential for investors.

The study offers an extensive evaluation of Porter's five forces analysis, SWOT analysis, and PESTEL analysis to provide data and information related to the business.

Porter's five forces model is analyzed to understand the overall competitive scenario that prevails in the market. The SWOT analysis also identifies the positive as well as the negative characteristics of market development which influences the company’s growth and development to sustain and survive in the long run. The PESTEL analysis identifies the macro (external) forces affecting the organization.

The report includes a thorough analysis of the company profiles of major companies operating in the global osteoarthritis therapeutics market and a comparative evaluation based on their business overviews, product offering, geographic presence, market share, business strategy, recent developments, product development & innovations, joint ventures, partnerships, mergers & acquisitions, expansions, SWOT analysis, and key financial information. It helps in evaluating the overall competition present in the market scenario.

Request For Request Sample

To receive a sample copy of this report, please complete the form below

Full Name

Company Name

Designation/Position

Contact

Region/Country

Message

Kindly share your specific requirement (if any), so we can get back to you with a solution

TABLE OF CONTENTS
1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. SCOPE OF THE STUDY
1.3. GEOGRAPHIC SCOPE
1.4. MARKET DEFINITION
1.5. CURRENCY CONSIDERATION
1.6. YEAR CONSIDERATION
2. RESEARCH METHODOLOGY AND ASSUMPTIONS
2.1. SECONDARY RESEARCH
2.2. PRIMARY RESEARCH
2.3. MARKET BREAKUP AND DATA TRIANGULATION
2.4. MARKET SIZE ESTIMATION
2.4.1. BOTTOM UP APPROACH
2.4.2. TOP DOWN APPROACH
2.5. ASSUMPTION
3. EXECUTIVE SUMMARY
3.1. KEY MARKET INSIGHTS
3.2. SEGMENTATION OUTLOOK
3.3. COMPANY OUTLOOK
4. PREMIUM INSIGHTS
4.1. IMPACT OF COVID-19 ON MARKET
4.2. INDUSTRY ROAD MAP
4.3. INDUSTRY TREND
4.4. INDUSTRY SWOT ANALYSIS
4.5. MARKET ATTRACTIVENESS ANALYSIS
4.5.1. MARKET ATTRACTIVENESS BY SEGMENTS
4.5.1.1. OSTEOARTHRITIS THERAPEUTICS MARKET ATTENTIVENESS BY DRUG TYPE
4.5.1.2. OSTEOARTHRITIS THERAPEUTICS MARKET ATTENTIVENESS BY ANATOMY
4.5.1.3. OSTEOARTHRITIS THERAPEUTICS MARKET ATTENTIVENESS BY ROUTE OF ADMINISTRATION
4.5.1.4. OSTEOARTHRITIS THERAPEUTICS MARKET ATTENTIVENESS BY DISTRIBUTION CHANNEL
4.5.2. MARKET ATTRACTIVENESS BY REGION
4.5.2.1. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.2. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.3. ASIA PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.4. SOUTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.5. MIDDLE EAST AND AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET ATTENTIVENESS BY COUNTRY
4.6. PORTER’S FIVE FORCES ANALYSIS
4.6.1. THREAT OF NEW ENTRANTS
4.6.2. THREAT OF SUBSTITUTES
4.6.3. BARGAINING POWER OF SUPPLIERS
4.6.4. BARGAINING POWER OF BUYERS
4.6.5. INTENSITY OF COMPETITIVE RIVALRY
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH & DEVELOPMENT COMPANIES
4.7.2. RAW MATERIAL/ COMPONENT SUPPLIERS
4.7.3. PRODUCT MANUFACTURERS
4.7.4. DISTRIBUTORS AND RETAILERS
4.7.5. END-USER INDUSTRIES
4.7.6. POST-SALES SERVICE PROVIDERS
4.8. FACTORS AFFECTING THE MARKET
4.8.1. MACRO FACTORS AFFECTING THE MARKET
4.8.2. MICRO FACTORS AFFECTING THE MARKET
4.8.3. PESTEL ANALYSIS
4.9. YEAR ON YEAR GROWTH RATE OF OSTEOARTHRITIS THERAPEUTICS
4.10. LIST OF SUPPLIERS
4.11. LIST OF BUYERS
4.12. COUNTRY LEVEL ANALYSIS
4.13. RULES AND REGULATION
5. MARKET DYNAMICS
5.1. MARKET DRIVERS
5.1.1. INCREASING GOVT. INVESTMENT IN CELL-BASED RESEARCH
5.1.2. INCREASING ADOPTION OF PAIN MEDICATIONS
5.2. MARKET RESTRAINTS
5.2.1. ADVERSE EFFECTS OF OSTEOARTHRITIS THERAPEUTIC DRUGS
5.3. MARKET OPPORTUNITIES
5.4. MARKET CHALLENGES
6. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET INSIGHTS AND FORECAST ANALYSIS, BY ANATOMY - 2017-2028
6.1. KEY FINDINGS
6.2. KNEE
6.3. HIP
6.4. HAND
6.5. SMALL-JOINT
7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET INSIGHTS AND FORECAST ANALYSIS, BY DRUG TYPE - 2017-2028
7.1. KEY FINDINGS
7.2. VISCOSUPPLEMENTATION AGENTS
7.3. NSAIDS
7.4. ANALGESICS
7.5. CORTICOSTEROIDS
8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET INSIGHTS AND FORECAST ANALYSIS, BY ROUTE OF ADMINISTRATION - 2017-2028
8.1. KEY FINDINGS
8.2. ORAL
8.3. TOPICAL
8.4. PARENTERAL
9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET INSIGHTS AND FORECAST ANALYSIS, BY DISTRIBUTION CHANNEL- 2017-2028
9.1. KEY FINDINGS
9.2. HOSPITAL PHARMACIES
9.3. ONLINE PHARMACIES
9.4. RETAIL PHARMACIES
10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET INSIGHTS AND FORECAST ANALYSIS, BY REGIONAL - 2017-2028
10.1. KEY FINDINGS
10.2. NORTH AMERICA
10.3. EUROPE
10.4. ASIA PACIFIC
10.5. SOUTH AMERICA
10.6. MIDDLE EAST & AFRICA
11. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
11.1. BY COUNTRY
11.1.1. U.S.
11.1.2. CANADA
11.1.3. MEXICO
12. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
12.1. BY COUNTRY
12.1.1. GERMANY
12.1.2. U.K.
12.1.3. FRANCE
12.1.4. ITALY
12.1.5. SPAIN
12.1.6. SWEDEN
12.1.7. BELGIUM
12.1.8. TURKEY
12.1.9. RUSSIA
12.1.10. POLAND
12.1.11. SWITZERLAND
12.1.12. NETHERLANDS
12.1.13. REST OF EUROPE
13. ASIA PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
13.1. BY COUNTRY
13.1.1.1. JAPAN
13.1.1.2. CHINA
13.1.1.3. INDIA
13.1.1.4. AUSTRALIA
13.1.1.5. SOUTH KOREA
13.1.1.6. MALAYSIA
13.1.1.7. INDONESIA
13.1.1.8. VIETNAM
13.1.1.9. NEW ZEALAND
13.1.1.10. PHILIPPINES
13.1.1.11. TAIWAN
13.1.1.12. SINGAPORE
13.1.1.13. REST OF ASIA-PACIFIC
14. SOUTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
14.1. BY COUNTRY
14.1.1.1. BRAZIL
14.1.1.2. ARGENTINA
14.1.1.3. CHILE
14.1.1.4. COLOMBIA
14.1.1.5. REST OF SOUTH AMERICA
15. MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
15.1. BY COUNTRY
15.1.1.1. SOUTH AFRICA
15.1.1.2. U.A.E.
15.1.1.3. SAUDI ARABIA
15.1.1.4. REST OF MIDDLE EAST AND AFRICA
16. COMPETITIVE LANDSCAPE
16.1. MARKET SHARE OF KEY PLAYERS IN POWER TOOL MARKET
16.1.1. GLOBAL MARKET SHARE ANALYSIS
16.1.2. NORTH AMERICA MARKET SHARE ANALYSIS
16.1.3. EUROPE MARKET SHARE ANALYSIS
16.1.4. ASIA PACIFIC MARKET SHARE ANALYSIS
16.1.5. SOUTH AMERICA MARKET SHARE ANALYSIS
16.1.6. MIDDLE EAST & AFRICA MARKET SHARE ANALYSIS
16.2. LEADERSHIP MAPPING
16.2.1. VISIONARY PLAYERS
16.2.2. INNOVATORS PLAYERS
16.2.3. DYNAMIC DIFFERENTIATORS
16.2.4. EMERGING COMPANIES
16.3. COMPETITIVE SCENARIO AND TRENDS
16.3.1. MERGERS & ACQUISITIONS
16.3.2. PRODUCT LAUNCHES AND DEVELOPMENTS
16.3.3. PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
16.3.4. EXPANSIONS
17. COMPANY PROFILES
17.1.1. SANOFI
17.1.1.1. COMPANY OVERVIEW
17.1.1.2. COMPANY SNAPSHOT
17.1.1.3. FINANCIAL ANALYSIS
17.1.1.3.1. REVENUE ANALYSIS
17.1.1.3.2. SALES ANALYSIS
17.1.1.3.3. PRICE ANALYSIS
17.1.1.3.4. MARGIN ANALYSIS
17.1.1.4. GEOGRAPHICAL PRESENCE
17.1.1.4.1. NORTH AMERICA
17.1.1.4.2. EUROPE
17.1.1.4.3. ASIA PACIFIC
17.1.1.4.4. SOUTH AMERICA
17.1.1.4.5. MIDDLE EAST & AFRICA
17.1.1.5. PRODUCT PORTFOLIO
17.1.1.6. SWOT ANALYSIS
17.1.1.7. RECENT DEVELOPMENT
17.1.2. HORIZON THERAPEUTICS PLC
17.1.3. JOHNSON & JOHNSON
17.1.4. GLAXOSMITHKLINE PLC
17.1.5. BAYER AG
17.1.6. ABBOTT
17.1.7. PFIZER
17.1.8. ELI LILLY
17.1.9. ANIKA THERAPEUTICS
17.1.10. NOVARTIS AG
17.1.11. FERRING PHARMACEUTICALS
17.1.12. BIOVENTUS
17.1.13. ZIMMER BIOMET HOLDINGS
17.1.14. FIDIAFARMACEUTICIS.P.A.
17.1.15. FLEXION THERAPEUTICS
17.1.16. PHARMED LIMITED
17.1.17. VIRCHOW BIOTECH
18. STRATEGIC RECOMMENDATIONS
LIST OF TABLE
1. RESEARCH ASSUMPTION
2. COVID-19 IMPACT ON MARKET
3. MAJOR DEVELOPMENTS BY VARIOUS COMPANIES
4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
5. GLOBAL KNEE OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
6. GLOBAL HIP OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
7. GLOBAL HAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
8. GLOBAL SMALL-JOINT OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
10. GLOBAL VISCOSUPPLEMENTATION AGENTS OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
11. GLOBAL NSAIDS OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
12. GLOBAL ANALGESICS OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
13. GLOBAL CORTICOSTEROIDS OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
14. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
15. GLOBAL ORAL OSTEOARTHRITIS THERAPEUTICS, BY REGION, 2017–2028 REVENUE (USD MILLION)
16. GLOBAL TOPICAL OSTEOARTHRITIS THERAPEUTICS, BY REGION, 2017–2028 REVENUE (USD MILLION)
17. GLOBAL PARENTERAL OSTEOARTHRITIS THERAPEUTICS, BY REGION, 2017–2028 REVENUE (USD MILLION)
18. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
19. GLOBAL HOSPITAL PHARMACIES OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
20. GLOBAL ONLINE PHARMACIES OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
21. GLOBAL RETAIL PHARMACIES OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
22. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY NORTH AMERICA, 2017–2028 REVENUE (USD MILLION)
23. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
24. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
25. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
26. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
27. U.S. OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
28. U.S. OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
29. U.S. OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
30. U.S. OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
31. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
32. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
33. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
34. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
35. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
36. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
37. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
38. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
39. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
40. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
41. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
42. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
43. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
44. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
45. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
46. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
47. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
48. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
49. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
50. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
51. U.K. OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
52. U.K. OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
53. U.K. OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
54. U.K. OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
55. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
56. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
57. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
58. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
59. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
60. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
61. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
62. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
63. SWEDEN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
64. SWEDEN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
65. SWEDEN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
66. SWEDEN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
67. BELGIUM OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
68. BELGIUM OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
69. BELGIUM OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
70. BELGIUM OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
71. TURKEY OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
72. TURKEY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
73. TURKEY OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
74. TURKEY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
75. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
76. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
77. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
78. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
79. POLAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
80. POLAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
81. POLAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
82. POLAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
83. SWITZERLAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
84. SWITZERLAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
85. SWITZERLAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
86. SWITZERLAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
87. NETHERLANDS OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
88. NETHERLANDS OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
89. NETHERLANDS OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
90. NETHERLANDS OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
91. ASIA PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
92. ASIA PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
93. ASIA PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
94. ASIA PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
95. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
96. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
97. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
98. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
99. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
100. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
101. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
102. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
103. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
104. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
105. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
106. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
107. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
108. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
109. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
110. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
111. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
112. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
113. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
114. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
115. INDONESIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
116. INDONESIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
117. INDONESIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
118. INDONESIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
119. VIETNAM OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
120. VIETNAM OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
121. VIETNAM OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
122. VIETNAM OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
123. NEW ZEALAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
124. NEW ZEALAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
125. NEW ZEALAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
126. NEW ZEALAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
127. PHILIPPINES OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
128. PHILIPPINES OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
129. PHILIPPINES OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
130. PHILIPPINES OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
131. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
132. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
133. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
134. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
135. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNELR, 2017–2028 REVENUE (USD MILLION)
136. SINGAPORE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
137. SINGAPORE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
138. SINGAPORE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
139. SINGAPORE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNELR, 2017–2028 REVENUE (USD MILLION)
140. SOUTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
141. SOUTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
142. SOUTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
143. SOUTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNELR, 2017–2028 REVENUE (USD MILLION)
144. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
145. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
146. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
147. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
148. ARGENTINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
149. ARGENTINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
150. ARGENTINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
151. ARGENTINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
152. CHILE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
153. CHILE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
154. CHILE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
155. CHILE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
156. COLOMBIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
157. COLOMBIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
158. COLOMBIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
159. COLOMBIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
160. MIDDLE EAST AND AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
161. MIDDLE EAST AND AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
162. MIDDLE EAST AND AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
163. MIDDLE EAST AND AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
164. UAE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
165. UAE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
166. UAE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
167. UAE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
168. SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
169. SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
170. SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
171. SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
172. SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
173. SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
174. SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
175. SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)
176. REST OF MEAOSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2017–2028 REVENUE (USD MILLION)
177. REST OF MEAOSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2028 REVENUE (USD MILLION)
178. REST OF MEAOSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2028 REVENUE (USD MILLION)
179. REST OF MEAOSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2028 REVENUE (USD MILLION)

LIST OF FIGURE
1. RESEARCH DESIGN
2. SCOPE OF THE STUDY
3. GEOGRAPHIC SCOPE
4. CURRENCY CONSIDERATION
5. YEAR CONSIDERATION
6. MARKET ESTIMATION
7. RESEARCH METHODOLOGY
8. DATA TRIANGULATION
9. COVID-19 IMPACT ON MARKET
10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ATTRACTIVENESS ANALYSIS BY DRUG TYPE
11. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ATTRACTIVENESS ANALYSIS BY ANATOMY
12. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ATTRACTIVENESS ANALYSIS BY ROUTE OF ADMINISTRATION
13. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ATTRACTIVENESS ANALYSIS BY DISTRIBUTION CHANNEL
14. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ATTRACTIVENESS ANALYSIS BY REGION
15. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ATTRACTIVENESS ANALYSIS BY COUNTRY
16. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET: DYNAMICS
17. PESTEL ANALYSIS
18. SWOT ANALYSIS
19. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ANALYSIS BY REGION
20. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ANALYSIS BY DRUG TYPE
21. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ANALYSIS BY ANATOMY
22. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
23. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL
24. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ANALYSIS BY NORTH AMERICA
25. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ANALYSIS BY EUROPE
26. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ANALYSIS BY ASIA PACIFIC
27. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ANALYSIS BY SOUTH AMERICA
28. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET ANALYSIS BY MIDDLE EAST & AFRICA
29. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COMPANY (2020)
30. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COMPANY (2020)
31. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COMPANY (2020)
32. ASIA PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COMPANY (2020)
33. SOUTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COMPANY (2020)
34. MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COMPANY (2020)